Newswise — Professor Moss has served as consultant to several drug companies that have introduced new anesthetics, including opiates and muscle relaxants. A special area of his expertise involves adverse reactions to anesthetic drugs and adjuvants in the perioperative period. He has published extensively on the effects of anesthetic drugs and agents on smooth muscle (vascular, ureteral and enteric) and on the effect of sex hormones on the cerebral and coronary vessels. His areas of interest include a study of the influence of dietary glycoalkaloids on cholinesterase function, studies of herbal medications in the perioperative period, and the development of methylnaltrexone (MNTX), a quaternary peripheral opiate antagonist that relieves the peripheral side effects of opiates while preserving analgesia. Traditional laxative treatments are often ineffective for many chronic pain patients suffering with opioid-induced constipation. Approximately 80% of chronic pain patients with OIC that were taking laxative therapy continued to report difficulties dealing with their constipation symptoms, as documented by a large patient survey published in 2008 in Pain Medicine. One third of these chronic pain patients reported stopping or lowering their opioid dose in order to relieve their opioid induced constipation, resulting in increased pain levels.